Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: PAL who wrote (4328)	5/18/1998 8:02:00 PM
From: Andreas Helke	Respond to of 6136

EntreMed had the very substantial news from a newspaper article that its angiogenesis inhibitors will have its first trials in humans this year before they finish preclinical development and file the IND. I think that had far more influence on EntreMeds price rise than any news from other companies. Andreas

To: PAL who wrote (4328)	5/20/1998 1:47:00 AM
From: George T. Santamaria	Read Replies (2) \| Respond to of 6136

I believe that the reason the insiders are selling is that they have expiring stock options. Maybe what's wrong here is that the option plans are a bit too generous. After all I noticed that some form of dilution, probably stock options, brought the 0.45/share earnings for the recent quarter down to $0.41. Management should be generously rewarded when they work as hard as AGPH has, however, there should be incentives to keep them working hard. If the plans are too generous, they'll stop taking risks and they won't worry about what Wall St. thinks. Someone care to comment on what's going on with stock option plans? BTW, I have to laugh when a major brokerage house sets a target and does not hold themselves accountable when they miss by the country mile that both Elise Wang of PW and MS's Doug Lind have.